Please take care and rest.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Alibaba
BABA
Broadcom
AVGO
NVIDIA
NVDA
Taiwan Semiconductor
TSM
ASML Holding
ASML
US Stock MarketDetailed Quotes
EYPT EyePoint Pharmaceuticals
- 5.890
- -0.070-1.17%
Trading Feb 26 09:37 ET
402.00MMarket Cap-2.96P/E (TTM)
6.060High5.873Low46.40KVolume5.910Open5.960Pre Close275.73KTurnover0.11%Turnover RatioLossP/E (Static)68.25MShares27.84052wk High1.84P/B253.65MFloat Cap5.79052wk Low--Dividend TTM43.06MShs Float72.200Historical High--Div YieldTTM3.13%Amplitude2.190Historical Low5.942Avg Price1Lot Size
EyePoint Pharmaceuticals Stock Forum
Sign in to post a comment
$EyePoint Pharmaceuticals (EYPT.US)$ Traders Circulate Unconfirmed Report On Social Media That Eyepoint Pharmaceuticals Received National Medical Products Administration Approval Of Dexycu In China To Treat Post-Operative Inflammation Following Ocular Surgery
1
1
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER...
131
5
6
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
77
10
5
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If...
62
17
5
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
59
8
4
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
57
12
1
$EyePoint Pharmaceuticals (EYPT.US)$
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
EyePoint Pharmaceuticals announced positive six-month results from its Phase 2 VERONA clinical trial of DURAVYU™ for Diabetic Macular Edema (DME). The trial met its primary endpoint with both DURAVYU doses (1.34mg and 2.7mg) showing extended time to first supplemental injection versus aflibercept...
EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema Meeting Primary and Secondary Endpoints
EyePoint Pharmaceuticals announced positive six-month results from its Phase 2 VERONA clinical trial of DURAVYU™ for Diabetic Macular Edema (DME). The trial met its primary endpoint with both DURAVYU doses (1.34mg and 2.7mg) showing extended time to first supplemental injection versus aflibercept...
3
3
$EyePoint Pharmaceuticals (EYPT.US)$
Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds
Clinical Trial Success: EyePoint's DME Drug Reduces Treatment Burden by Two-Thirds
$EyePoint Pharmaceuticals (EYPT.US)$ Reuters· just
EyePoint Pharmaceuticals Inc - Primary Endpoint Achieved by Both Duravyu Doses
EyePoint Pharmaceuticals Inc - Primary Endpoint Achieved by Both Duravyu Doses
$EyePoint Pharmaceuticals (EYPT.US)$
EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(5.2%),TCG Crossover Fund II, L.P.(5.2%), etc.
EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-TCG Crossover GP II, LLC(5.2%),TCG Crossover Fund II, L.P.(5.2%), etc.
1
No comment yet
Trending Stocks
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Daight : easy way to confirm just check if the boss is has any connections to CCP or not.![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")